OPR10 Antibody

What is ORP10 and its primary cellular function?

ORP10 functions as a lipid transfer protein that forms a binary complex with ORP9 through their respective coiled-coil (CC) domains. This heterocomplex maintains phosphatidylinositol 4-phosphate (PI4P) homeostasis at endoplasmic reticulum-trans-Golgi network membrane contact sites (ER-TGN MCSs) and regulates vesicle trafficking. The complex targets the TGN through specific PH domain-PI4P interactions, with both proteins playing coordinated roles in maintaining lipid homeostasis and regulating vesicular transport between cellular compartments .

How does ORP10 interact with ORP9 in cellular contexts?

ORP10 and ORP9 form a binary complex through their coiled-coil domains, which are located in the linker region between the PH domain and ORD (OSBP-related domain). GST pull-down assays have confirmed that removal of either CC domain disrupts the association between these proteins. The interaction can be visualized using bimolecular fluorescence complementation (BiFC), which generates a strong signal at the ER-TGN interface. Importantly, ORP9 determines the subcellular localization of ORP10, as deletion of the CC domain prevents ORP10 from colocalizing with the ER .

What cellular phenotypes are observed when ORP10 is depleted?

Depletion of ORP10 leads to significantly elevated levels of PI4P at the TGN, similar to the effects observed when ORP9 is depleted. This disruption in PI4P homeostasis affects vesicle trafficking, with notable accumulation of vesicular stomatitis virus G protein (VSV-G) on the plasma membrane. These observations confirm ORP10's critical role in maintaining proper lipid distribution and vesicular transport processes. Interestingly, simultaneous depletion of both ORP9 and ORP10 does not increase TGN PI4P levels beyond what is observed in ORP9-depleted cells alone .

What epitopes should be targeted when selecting ORP10 antibodies for immunofluorescence studies?

For immunofluorescence studies of ORP10, researchers should select antibodies targeting epitopes in regions outside the coiled-coil (CC) domain that mediates interaction with ORP9. Antibodies recognizing the PH domain or ORD regions are often effective for visualizing ORP10 at ER-TGN membrane contact sites. When designing co-localization experiments, it's essential to use antibodies raised in different species for ORP10 and ORP9 to enable simultaneous detection. This approach has been successfully employed to visualize ORP10's association with TGN markers and the PI4P sensor P4C-SidC in confocal microscopy studies .

How can ORP10 antibodies be validated for specificity in western blotting applications?

Validation of ORP10 antibodies for western blotting should include multiple controls. First, compare protein detection in wild-type cells versus ORP10-depleted cells (using CRISPR-Cas9 or siRNA approaches) to confirm specificity. Second, perform overexpression experiments with tagged ORP10 constructs to verify that the antibody recognizes both endogenous and overexpressed protein. Third, conduct peptide competition assays where the antibody is pre-incubated with the immunizing peptide before western blotting. For heterocomplexes like ORP9-ORP10, co-immunoprecipitation followed by western blotting provides definitive validation of antibody specificity and interaction dynamics .

What controls are necessary when using ORP10 antibodies in immunoprecipitation experiments?

When using ORP10 antibodies for immunoprecipitation (IP), multiple controls are essential: (1) A negative control using non-immune IgG from the same species as the ORP10 antibody to identify non-specific binding; (2) Input samples representing 5-10% of the lysate used for IP to assess enrichment; (3) ORP10-depleted cell lysates as additional negative controls; (4) Reciprocal IP experiments using ORP9 antibodies to confirm the interaction. Mass spectrometry analysis following IP can further validate specificity and identify novel interaction partners, as demonstrated in studies that initially identified the ORP9-ORP10 complex. For quantitative co-IP studies, densitometric analysis should be employed to calculate relative binding affinities .

How can ORP10 antibodies be optimized for super-resolution microscopy of membrane contact sites?

For super-resolution microscopy of ORP10 at membrane contact sites, direct immunofluorescence approaches using primary antibodies conjugated to photo-switchable fluorophores (e.g., Alexa Fluor 647) provide optimal results. The key optimization steps include: (1) Fixation protocol adjustment—testing both paraformaldehyde (2-4%) and methanol fixation to determine which best preserves ORP10 epitopes while maintaining membrane structure; (2) Titration of antibody concentration (typically 1-5 μg/ml) to maximize signal-to-noise ratio; (3) Implementation of dual-color STORM or PALM imaging with <20 nm resolution to precisely map ORP10 distribution relative to ER and TGN markers. When studying the ORP9-ORP10 complex, orthogonal labeling strategies using antibodies against different domains of each protein enable accurate determination of protein orientation at MCSs .

What methodological approaches can resolve contradictory results when studying ORP10 lipid transfer function with antibodies?

When facing contradictory results in ORP10 lipid transfer studies using antibodies, a systematic troubleshooting approach is required: (1) Conduct epitope mapping of the antibodies to determine if they interfere with functional domains—antibodies targeting the ORD may inhibit lipid transfer while those against the CC domain might disrupt ORP9 interaction; (2) Implement complementary approaches such as FRET-based lipid transfer assays with purified proteins alongside antibody studies; (3) Develop domain-specific antibodies that distinguish between different conformational states of ORP10; (4) Utilize cells expressing endogenous ORP10 with mutations in key functional residues to differentiate between direct antibody interference and genuine biological effects. Finally, correlation of in vitro lipid transfer assays with cellular PI4P levels measured by PI4P sensors provides a comprehensive validation framework .

How can post-translational modifications of ORP10 be analyzed using specific antibodies?

Analysis of ORP10 post-translational modifications requires specialized antibodies and a multi-technique approach: (1) Develop or acquire phospho-specific antibodies targeting known or predicted phosphorylation sites, which can be validated using lambda phosphatase treatments; (2) Employ intact and subunit molecular mass analysis using ultraperformance liquid chromatography (UPLC) coupled with high-resolution mass spectrometry (HRMS) to identify the exact mass shifts corresponding to modifications; (3) Perform sequential immunoprecipitation with general ORP10 antibodies followed by immunoblotting with modification-specific antibodies (e.g., anti-phospho, anti-ubiquitin); (4) Use proximity ligation assays with pairs of antibodies (one against ORP10, one against the modification) to visualize modified populations in situ. These approaches provide complementary information about the regulatory modifications affecting ORP10 function .

What are the optimal sample preparation techniques when using ORP10 antibodies for immunohistochemistry?

For optimal immunohistochemistry with ORP10 antibodies, tissue preparation is critical: (1) Use freshly prepared 4% paraformaldehyde fixation for 24-48 hours, followed by paraffin embedding; (2) Perform antigen retrieval using citrate buffer (pH 6.0) with pressure cooking for 15-20 minutes to expose ORP10 epitopes; (3) Block endogenous peroxidases with 3% hydrogen peroxide and prevent non-specific binding with 5% normal serum from the same species as the secondary antibody; (4) Optimize primary antibody concentration through titration experiments (typically 1:100 to 1:500 dilutions) and incubate overnight at 4°C in a humidified chamber; (5) Use highly cross-adsorbed secondary antibodies to prevent cross-reactivity. For multiplex immunohistochemistry, tyramide signal amplification allows sequential detection of ORP10 alongside organelle markers or ORP9 .

How can researchers quantitatively assess ORP10-ORP9 interactions using antibody-based approaches?

Quantitative assessment of ORP10-ORP9 interactions can be achieved through multiple complementary approaches: (1) Förster Resonance Energy Transfer (FRET) analysis using secondary antibodies labeled with appropriate donor-acceptor fluorophore pairs (e.g., Alexa Fluor 488 and Alexa Fluor 555); (2) Proximity Ligation Assay (PLA) with species-specific antibodies against ORP10 and ORP9, which generates quantifiable fluorescent dots only when proteins are within 40 nm of each other; (3) Co-immunoprecipitation followed by western blotting with band intensity quantification through densitometry; (4) Bimolecular Fluorescence Complementation (BiFC) assays using cells expressing split fluorescent protein-tagged ORP10 and ORP9. The latter approach has confirmed that these proteins interact at the ER-TGN interface, with the interaction being dependent on their coiled-coil domains .

What protocols ensure reproducible co-immunoprecipitation of ORP10-associated complexes in different cell types?

To ensure reproducible co-immunoprecipitation of ORP10-associated complexes across different cell types, follow this standardized protocol: (1) Harvest cells in a mild lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate) supplemented with protease inhibitors, phosphatase inhibitors, and 1 mM DTT; (2) Standardize protein concentration to 1-2 mg/ml using Bradford or BCA assays; (3) Pre-clear lysates with 25 μl of Protein A/G beads per 1 ml of lysate for 1 hour at 4°C; (4) Incubate pre-cleared lysates with 2-5 μg of ORP10 antibody overnight at 4°C with gentle rotation; (5) Capture immune complexes with 50 μl of Protein A/G beads for 2 hours; (6) Wash beads extensively (4-5 times) with decreasing salt concentrations; (7) Elute bound proteins with SDS sample buffer and analyze by immunoblotting. When comparing different cell types, normalization to ORP10 input levels is essential for accurate interpretation of interaction differences .

How should researchers interpret discrepancies between immunofluorescence and biochemical data regarding ORP10 localization?

When facing discrepancies between immunofluorescence and biochemical data on ORP10 localization, consider these methodological factors: (1) Fixation artifacts—paraformaldehyde can disrupt membrane structures and potentially reorganize lipid-binding proteins like ORP10; comparative studies using live-cell imaging of fluorescently tagged ORP10 may resolve these differences; (2) Extraction effects—membrane fractionation protocols might disrupt weak interactions between ORP10 and cellular membranes, causing proteins to appear in incorrect fractions; (3) Antibody accessibility—the ORP10 epitope may be masked in certain conformational states or by interacting partners like ORP9; (4) Cell type-specific expression levels of interaction partners—ORP9 levels influence ORP10 localization, so varying expression ratios in different cell types may explain localization discrepancies. Integrating proximity labeling techniques (BioID or APEX) with traditional approaches provides complementary evidence of protein localization .

What strategies help resolve non-specific binding issues with ORP10 antibodies in immunoprecipitation experiments?

To address non-specific binding in ORP10 immunoprecipitation experiments, implement these strategies: (1) Optimize antibody amounts—titrate down from standard concentrations (5 μg) to find the minimum effective amount; (2) Increase stringency of wash buffers by adjusting salt concentration (150-500 mM NaCl) and detergent type/concentration (switch from NP-40 to Triton X-100 or use dual detergent approaches); (3) Add competing proteins like BSA (0.1-1%) to blocking and antibody incubation steps; (4) Perform sequential immunoprecipitation where the first IP removes non-specific binders; (5) Use magnetic beads instead of agarose to enable more thorough washing; (6) Pre-adsorb antibodies against cell lysates from ORP10-knockout cells to remove cross-reactive antibodies. Compare results across multiple independent ORP10 antibodies recognizing different epitopes to confirm specificity of interactions .

How can researchers differentiate between direct and indirect interactions in ORP10-ORP9 complex studies?

Differentiating direct from indirect interactions in ORP10-ORP9 complex studies requires multiple orthogonal approaches: (1) In vitro binding assays using recombinant proteins—purified ORP10 and ORP9 have been shown to directly interact through their coiled-coil domains in GST pull-down experiments; (2) Yeast two-hybrid or split-ubiquitin assays to test direct interactions in cellular contexts without mammalian bridging proteins; (3) Sequential deletion and point mutation analysis of protein domains—specific mutations in the coiled-coil domain disrupt the interaction, confirming its direct nature; (4) Crosslinking mass spectrometry (XL-MS) to map exact residues involved in direct contacts; (5) Single-molecule FRET using purified proteins to observe direct binding events and determine binding kinetics. The combination of these techniques has established that ORP9 and ORP10 form a binary complex through direct interaction of their coiled-coil domains, rather than via intermediate proteins .